2 news items
Spyre Therapeutics Appoints Accomplished Biopharma Leader Dr. Sandra Milligan to its Board of Directors
SYRE
15 May 24
to collaborate in their goal to drive meaningful advancements in IBD treatment toward improving lives."
Dr
Spyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
SYRE
9 May 24
approach combines best-in-class antibody engineering, rational therapeutic combinations, and precision immunology with the goal of maximizing efficacy
- Prev
- 1
- Next